These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34187274)

  • 21. Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged.
    Firoozi F; Gill B; Ingber MS; Moore CK; Rackley RR; Goldman HB; Vasavada SP
    J Urol; 2013 Aug; 190(2):594-7. PubMed ID: 23499745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
    Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
    J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Multicenter Study Evaluating the FREquency of Use and Efficacy of a Novel Closed-Loop Wearable Tibial Neuromodulation System for Overactive Bladder and Urgency Urinary Incontinence (FREEOAB).
    Goudelocke C; Sobol J; Poulos D; Enemchukwu E; Zaslau S; Dhir R
    Urology; 2024 Jan; 183():63-69. PubMed ID: 37944596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacral neuromodulation system for treating refractory overactive bladder.
    Phillips A
    Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study.
    Gilling P; Meffan P; Kaaki B; MacDiarmid S; Lucente V; Clark M; Sen SK; English S; Sand PK
    Urology; 2021 Nov; 157():71-78. PubMed ID: 34048826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Sacral Neuromodulation in Patients with Prior Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse.
    Bartley JM; Ramirez V; Killinger KA; Boura JA; Gupta P; Gaines N; Gilleran JP; Peters KM
    Female Pelvic Med Reconstr Surg; 2017; 23(1):8-12. PubMed ID: 27636222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral Neuromodulation.
    Chartier-Kastler E; Le Normand L; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Karsenty G; Song S; Keller DUJ; Cornu JN
    Eur Urol Focus; 2023 Sep; 9(5):765-772. PubMed ID: 37019729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence.
    MacDiarmid S; Staskin DR; Lucente V; Kaaki B; English S; Gilling P; Meffan P; Clark M; Sand PK; Sen SK; Rovner E
    J Urol; 2019 May; 201(5):967-972. PubMed ID: 31009968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
    Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
    Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence.
    Hendrickson WK; Zhang C; Jelovsek JE; Nygaard IE; Presson AP
    J Urol; 2024 Jan; 211(1):134-143. PubMed ID: 37871326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
    Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
    Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial.
    Amundsen CL; Richter HE; Menefee S; Vasavada S; Rahn DD; Kenton K; Harvie HS; Wallace D; Meikle S
    Contemp Clin Trials; 2014 Mar; 37(2):272-83. PubMed ID: 24486637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
    Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA
    J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
    Neurourol Urodyn; 2018 Feb; 37(S2):S17-S22. PubMed ID: 29336058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
    Richter HE; Amundsen CL; Erickson SW; Jelovsek JE; Komesu Y; Chermansky C; Harvie HS; Albo M; Myers D; Gregory WT; Wallace D;
    J Urol; 2017 Oct; 198(4):890-896. PubMed ID: 28501541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.